{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=54",
    "query": {
      "condition": "Safety Study",
      "page": 54
    },
    "page_size": 10
  },
  "pagination": {
    "page": 54,
    "page_size": 10,
    "total_count": 33598,
    "total_pages": 3360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=55&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=53&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T13:38:43.933Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01296711",
      "title": "Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "CDP6038 (olokizumab)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "UCB BIOSCIENCES, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2011-03-07",
      "completion_date": "2013-08-05",
      "has_results": true,
      "last_update_posted_date": "2022-04-14",
      "last_synced_at": "2026-11-19T13:38:43.933Z",
      "location_count": 50,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01296711"
    },
    {
      "nct_id": "NCT07637071",
      "title": "Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Androgenic Alopecia",
        "Hair Loss/Baldness",
        "Hair Thinning"
      ],
      "interventions": [
        {
          "name": "Xtressé Hair Growth Gummies",
          "type": "OTHER"
        },
        {
          "name": "Placebo Comparator",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Restore Biologics Holdings, Inc. dba Xtressé",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2026-09-23",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-19T13:38:43.933Z",
      "location_count": 2,
      "location_summary": "Maitland, Florida • Port Orange, Florida",
      "locations": [
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07637071"
    },
    {
      "nct_id": "NCT02105571",
      "title": "Evaluation of Safety and Health Involvement For Truck Drivers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 452,
      "start_date": "2012-04-23",
      "completion_date": "2017-04",
      "has_results": true,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-11-19T13:38:43.933Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02105571"
    },
    {
      "nct_id": "NCT01818492",
      "title": "Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Primary Haemophagocytic Lymphohistiocytosis"
      ],
      "interventions": [
        {
          "name": "NI-0501",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Swedish Orphan Biovitrum",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 45,
      "start_date": "2013-07",
      "completion_date": "2019-01",
      "has_results": true,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-11-19T13:38:43.933Z",
      "location_count": 8,
      "location_summary": "Aurora, Colorado • Wilmington, Delaware • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01818492"
    },
    {
      "nct_id": "NCT01443936",
      "title": "Experimental AD4-H5-VTN Vaccine in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "H5N1 Influenza"
      ],
      "interventions": [
        {
          "name": "Ad4-H5-VTN vaccination-tonsillar route",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad4-H5-vaccination-oral route",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 96,
      "start_date": "2011-09-14",
      "completion_date": "2019-04-24",
      "has_results": false,
      "last_update_posted_date": "2019-12-16",
      "last_synced_at": "2026-11-19T13:38:43.933Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01443936"
    },
    {
      "nct_id": "NCT01212744",
      "title": "Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Phenylketonuria"
      ],
      "interventions": [
        {
          "name": "rAvPAL-PEG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 16,
      "start_date": "2011-03",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-11-19T13:38:43.933Z",
      "location_count": 9,
      "location_summary": "Aurora, Colorado • Gainesville, Florida • Louisville, Kentucky + 6 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01212744"
    },
    {
      "nct_id": "NCT04708834",
      "title": "Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obsessive Compulsive Disorder"
      ],
      "interventions": [
        {
          "name": "Troriluzole (BHV-4157)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biohaven Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 772,
      "start_date": "2021-03-30",
      "completion_date": "2026-02-13",
      "has_results": false,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-11-19T13:38:43.933Z",
      "location_count": 147,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 119 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04708834"
    },
    {
      "nct_id": "NCT03972709",
      "title": "A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Degeneration, Age-Related",
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "Galegenimab",
          "type": "DRUG"
        },
        {
          "name": "Sham Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 372,
      "start_date": "2019-06-03",
      "completion_date": "2022-10-27",
      "has_results": true,
      "last_update_posted_date": "2024-03-27",
      "last_synced_at": "2026-11-19T13:38:43.933Z",
      "location_count": 72,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 65 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03972709"
    },
    {
      "nct_id": "NCT05319015",
      "title": "Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Neoadjuvant Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Neoadjuvant Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection",
          "type": "PROCEDURE"
        },
        {
          "name": "Adjuvant Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-01-06",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-11-19T13:38:43.933Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05319015"
    },
    {
      "nct_id": "NCT01128335",
      "title": "Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Transplantation"
      ],
      "interventions": [
        {
          "name": "MMF(1000mg bid) + tacrolimus + standard of care medications",
          "type": "DRUG"
        },
        {
          "name": "sotrastaurin (200mg bid) + tacrolimus + standard of care medications",
          "type": "DRUG"
        },
        {
          "name": "sotrastaurin (300 mg bid) + tacrolimus + standard of care medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2010-04",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2020-12-22",
      "last_synced_at": "2026-11-19T13:38:43.933Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • San Francisco, California • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01128335"
    }
  ]
}